Antitumor effect of anti-PD-L1 therapy was assessed in four syngeneic mouse tumor models: MC38 colon adenocarcinoma, B16 melanoma, and two triple-negative mammary cancers: AT-3 derived from the PyMT-MMTV model on an H-2b background and 4T1 on an H-2d background. This evidence concerns the gene CD274 and melanoma.